Company Overview
Skymab Biotherapeutics is a CEA* spin-off biotech company committed to the development of anti-GPCR Antibody Drug Conjugates (ADC).
Skymab was founded by enthusiastic scientists and entrepreneurs, thrilled to combine the most valuable technical knowhow in ADC development with the expertise in GPCR to create innovative tailored ADCs that treat patients with high unmet medical needs in oncology.
*French Atomic Agency (CEA), the most innovative public research organization in Europe according to a REUTERS ranking.
Our mission
Using our cutting edge ADC technology platform associated with our knowhow process to identifying GPCRs targets meeting ideal ADC targets, we aim at pioneering a new range of first and best in class ADCs intended to diagnostic and therapeutic applications for patients unserved by established ADCs.